Mondelez Lifts 2026 Organic Growth Outlook on Improving Volume and Mix

What happened

Mondelez has raised its 2026 organic growth forecast following first-half results that showed improving volume/mix and pricing strength across key regions, a notable shift from the negative volume/mix trends that persisted through 2025. The company had been grappling with broad input inflation—especially cocoa—and consumer down-trading, which compressed margins and forced a cut to 2025 guidance, but the latest update suggests that some of the volume repair management targeted may be materializing. The lift in outlook appears driven by better execution in North America and continued strength in emerging markets, although the announcement did not specify the magnitude of the increase or provide explicit margin or EPS guidance. This development aligns with the bull scenario outlined in the prior deep-value report, which required evidence of volume stabilization and margin recovery, but confirmation of EPS growth and gross margin improvement above 35% is still pending. Investors should treat this as an encouraging early signal rather than a definitive conclusion, as the company still faces structural cost pressures from tariffs and broad input inflation.

Implication

For investors, this news reduces the probability of the bear case where volumes remained persistently negative, but does not yet confirm a return to high-single-digit EPS growth. The next key catalysts are the company's Q2 and full-year earnings reports, where gross margin recovery and EPS guidance for 2027 will indicate whether cocoa deflation and operating leverage are flowing through as expected. If Mondelez can sustain positive volume/mix and show sequential gross margin improvement toward 35%, the likelihood of the bull scenario (implied value $65) increases, supporting a more constructive stance at current prices. However, if the volume improvement is modest or margin recovery stalls due to tariffs or persistent cost inflation, the base case (implied value $58) remains appropriate and the stock may offer limited upside from current levels. Given the stock's valuation at ~20x trough earnings and reliance on execution, investors should maintain a disciplined approach and consider adding only on signs of sustained EPS acceleration, while trimming if the recovery stalls.

Thesis delta

The prior thesis called for waiting until either a lower entry price or clearer proof of margin and volume repair before increasing conviction. The latest news provides initial evidence of volume/mix improvement and a raised organic growth outlook, which partially satisfies the 'proof of repair' condition, though margin recovery remains unconfirmed. The thesis shifts from 'wait for proof' to 'early proof emerging', but we maintain a cautious stance pending confirmation of EPS growth and gross margin expansion in upcoming quarters.